More positive data on the Pfizer/BioNTech new crown vaccine has been released.

Introduction: BioNTech and Pfizer recently released safety and immunogenicity data from a Phase 1 clinical study in the BNT162 mRNA Basic Vaccine Project.
last month, BioNTech and Pfizer released positive data on the phase I/II trial of the newly developed mRNA new crown vaccine BNT1621b1 Germany I/II and said they had reached a $1.95 billion agreement with the U.S. government for BNT162.
(Related reading: $1.95 billion!) Pfizer/BioNTech's new crown vaccine received a major U.S. government order) Recently, the two companies also released BNT162 mRNA basic vaccine project in a phase 1 clinical study of safety and immunogenicity data.
results showed that subjects receiving the experimental vaccine BNT162b2 (30 g) had SARS-CoV in young and middle-aged people (18-55 years) seven days after the second injection. The -2 meso-geometric average titration (GMT) was 3.8 times higher than that of recovering patients with COVID-19, while the GMT of older persons (65-85 years old) was 1.6 times higher than that of recovering patients.
, the average concentration of anti-SARS-CoV-2 antibodies produced by the BNT162b2 vaccine was higher, showing strong immunogenicity in both young and old adults.
, the study compared the effects of the two-dose experimental mRNA vaccine BNT162b1 and BNT162b2.
in the subjects, BNT162b1 and BNT162b2 induced similar dose-dependent SARS-CoV-2 neutral and antibody GMTs.
after the second inoculation, there was a significant increase in GMTs in the participants, showing significant benefits from the two-dose vaccination programme.
but from a safety point of view, the systemic event after inoculation of BNT162b2 is lighter than BNT162b1.
in all populations, the BNT162b2 vaccine was well-resistant, with less than 20% of the subjects suffering from mild to moderate fever.
severe systemic events (including fatigue, headache, chills, muscle pain, and joint pain) occur only in a small number of younger participants and are short-lived and controllable.
companies have pushed the two-dose program of the 30-g dose-level BNT162b2 vaccine to a phase 2/3 clinical trial, with 30,000 participants expected to be recruited in the United States, Argentina and Brazil.
BioNTech is still evaluating the T-cell immune response caused by BNT162b2.
, the two companies announced that participants vaccinated against BNT162b2 showed a broader identification of specific T-cell reactions to SARS-CoV-2 echizon antigens than the BNT162b1 candidate vaccine. Moreover, BNT162b2 can induce high-intensity CD4 plus and CD8-T cell reactions for the remaining echithybus glycogens not included in the candidates for the subject binding domain (RBD) and BNT162b1 vaccines at the same time.
BNT162b2 is an mRNA vaccine that encodes optimized SARS-CoV-2 full-length echisaccharin.
had just been screened at the end of July and was in advanced clinical trials a month later, and Pfizer and BioNTech had planned to seek regulatory approval for the vaccine as early as October and supply 100 million doses worldwide by the end of the year and 1.3 billion doses by the end of 2021.
fast-growing vaccines are Modelna mRNA-1273, AstraZenecom AZD1222, and Johnson and Johnson Ad26.COV2-S.
, it remains to be seen whether any of the COVID-19 vaccine candidates will provide long-term protection against viral infections each year.
currently, phase 1 clinical data focus only on the production of negativebodies or the stimulation of vaccines to human T-cells, and these measures may not translate into real protective effects.
clearly, the measure that researchers should look for in Phase 3 trials is the actual effectiveness of vaccines in preventing infection.
the COVID-19 global pandemic has indeed opened up a new model of vaccine research and development.
in addition to the key research and development leader mentioned above, early trials of more vaccines are rapidly under way (see figure below).
the most important of these is Curevac's candidate vaccine CVnCoV, which has been rapidly advancing Phase 2 clinical studies, but will not be available until the fourth quarter of this year.
said last week that it had tentatively negotiated a vaccine for up to 405m doses to the EU.
addition, Gam-COVID-Vac, a vaccine for adenovirus developed by russia's Gamaleya Institute, has ceded attention.
said it had completed two phases of clinical studies, but no relevant human data had been released, and that it had been approved by Russian drug regulators this month without the support of phase 3 clinical and longer-term efficacy data.
: 1, Pfizer, Germany's BioNTech release new data on Covid-19 vaccine2, Next triggers in Covid-19 vaccine development.